Statins to protect the heart during HER2 breast cancer treatment
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed stage I to III breast cancer (including inflammatory breast cancer), and HER2-targeted therapy is planned
- You are age 18 or older
- Your baseline heart pumping function is good (LVEF is 50% or higher on an ultrasound/echocardiogram)
- You are not currently taking statins, and you have not had prior HER2-targeted treatment or anthracycline chemotherapy
- Your blood counts and organ tests (liver and kidneys) are within acceptable ranges
- You can attend study visits and give written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests if taking rosuvastatin (a cholesterol-lowering pill) can help prevent heart damage from anthracycline chemotherapy in women with breast cancer. If you are about to start this type of chemo and have not used statins before, you may qualify.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
This Phase 3 study tests whether taking atorvastatin (a cholesterol-lowering medicine) can improve outcomes for women with estrogen-receptor–positive breast cancer. It may help by affecting cancer-related pathways and reducing risk of recurrence or progression.
This trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted therapy) and lovastatin (a statin)—to treat advanced or metastatic breast cancer that has low levels of a protein called HER2. The goal is to see if this combination can slow or shrink the cancer.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
Hear when a new Cardiac Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.